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Abstract
Background: For resection of colorectal cancer (CRC) liver metastases, pre-operative portal vein
embolization (PVE) is used to increase the size of the future liver remnant (FLR) prior to advanced liver
resection when indicated. PVE is speculated to cause tumour progression, but only a limited number
of studies have analysed tumour growth after PVE in the context of pre-procedural chemotherapy,
which was the aim of this retrospective study.
Methods: Patients treated with stabilizing chemotherapy and PVE before liver resection for CRC
metastases were included. Tumour progression according to RECIST guidelines and a change in
tumour volume was analysed on computed tomography (CT) scans prior to chemotherapy, before PVE
and after PVE, respectively.
Results: Thirty-four patients were included, of whom 23 had bilobar disease. Of tumours in the
embolized lobe, 3/34 showed progression after PVE as compared with 3/23 in the non-embolized lobe
(P = 0.677). A decrease in tumour volume of 16% and 11% was noted in the embolized and non-em
bolized lobe, respectively (P = 0.368). Patients were off chemotherapy in a median of 16 days before
PVE. There was a linear correlation between the growth of tumours and time between the end of
chemotherapy and PVE (r = 0.25, P = 0.0005).
Conclusion: The rate of progression of CRC liver metastases after PVE and pre-procedural chemo-
therapy was lower in the present study as compared with previous reports. This applies to tumours in
both the embolized and non-embolized lobes and is associated with keeping the time between the
end of chemotherapy and PVE short.
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Introduction
Within 3 years after the diagnosis of colorectal cancer (CRC),
29% of patients will have developed liver metastases.1 One of
the criteria for resectability of CRC liver metastases is that a
sufficient future liver remnant (FLR) remains after resection.2
Pre-operative portal vein embolization (PVE) can generally
increase the FLR to 30% or more of the total functional liver
volume (tFLV),3,4 by causing atrophy of the embolized lobe
and hypertrophy of the contralateral lobe.5,6 In addition,
chemotherapy is often used before PVE, either for neoadjuvant
or downstaging purposes.
The risk for tumour progression in the neoadjuvant setting
with modern chemotherapeutic agents is low, around 5–7%.7,8
Tumour progression during chemotherapy is considered at
least a relative contraindication to advanced liver resection.9,10
For CRC liver metastases, there have been concerns about a
tumour growth-promoting effect by PVE.11,12 However, only a
few studies have considered tumour growth in the FLR with
special reference to chemotherapy.13,14
Objective
The aim of this study was to investigate the growth of liver
metastases after stabilization of the disease by chemotherapy
before PVE. In addition, this study aims to investigate if
tumour growth is different between tumours located in the
embolized lobe and those in the non-embolized liver lobe. If
pre-procedural chemotherapy can arrest tumour growth in the
FLR between PVE and resection, this could have an impact on
the indications for a two-stage hepatectomy (TSH).
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Patients and methods
Patients
Between 2005 and 2013, all patients treated with PVE at Skane
University Hospital, Lund, Sweden, and between 2004 and
2010 at Karolinska University Hospital, Stockholm, Sweden,
were identified. Of those, patients undergoing a PVE prior to a
planned resection of CRC liver metastases were selected,
including only patients who were treated with chemotherapy
within 2 months prior to PVE and achieving at least tumour
stabilization according to RECIST 1.1 guidelines.15 Exclusion
criteria were a previous liver resection or ablation (including
TSH), the absence of a follow-up abdominal computed tomog-
raphy (CT) scan within 2 months after PVE or absence of a
CT scan within 3 months prior to PVE.
Baseline characteristics on patient, disease and treatment
specifics were collected, such as age, body mass index (BMI),
occurrence of synchronous or metachronous metastases, the
number of liver metastases, size of the largest metastasis and
chemotherapy regimens. Synchronous metastatic disease was
defined as metastases occurring within 6 months after diagno-
sis of the colorectal cancer.
Abdominal CT scans were collected and studied on all
patients, using the images from before the start of chemother-
apy (CTpre-chemo), the most recent images before PVE, but not
longer than 3 months prior to PVE (CTpre-PVE), and follow-up
CT after PVE, at the latest 2 months after PVE (CTpost-PVE).
Liver metastases were deemed bilobar or unilobar according
to their locations. Tumours stretching across the Cantlie’s line
were defined as situated in either the left or right lobe accord-
ing to where its geometrical centre was located. tFLV was cal-
culated by subtracting the total tumour volume from the total
liver volume. In all patients, FLR was calculated for a potential
extended right-sided hemihepatectomy, therefore calculating
the volume of segments I–III according to the segments as
described by Couinaud.16
Information on eventual liver resection was collected,
including type of resection and whether a resection was radical
based on pathology. Resections were classified either as a right-
sided hemihepatectomy, i.e. segments V–VIII or an extended
right-sided hemihepatectomy, i.e. segments IV-VIII. Both
resection types were with or without additional atypical resec-
tions in remaining segments.
Outcome measures
Using RECIST 1.1 guidelines15 two target lesions were selected
in the right and two in the left lobe, or fewer lesions in case of
singular metastases or unilobar disease. By measuring the max-
imum diameter of the target lesions, tumour growth over time
was noted between CTpre-chemo and CTpre-PVE, representing the
effect of chemotherapy, as well as between CTpre-PVE and
CTpost-PVE, representing tumour growth after PVE. For the
right and the left lobe separately, the development between
two CT scans was classified as complete remission (CR), partial
regress (PR), stable disease (SD) or progressive disease (PD).
Also, the total volume of all metastases in the right and left
lobe, respectively, was calculated in all three CT scans, by out-
lining the tumours in each transversal image to calculate the
area, adding up all calculated areas from the different slides
and then multiplying by slide thickness, which was 5 mm or
less. Again, larger tumours occupying both the left and the
right liver lobe were determined to have their centre in one
lobe and were thus counted in one lobe only. Successively, the
change in tumour volume between CTpre-chemo and CTpre-PVE
was calculated by dividing the tumour volume pre-PVE by the
tumour volume pre-chemo and multiplying by 100%. Hence,
values between 0 and 100 represent tumour shrinkage whereas
values over 100 represent tumour growth. The same was done
to analyse the change in tumour volume between CTpre-PVE
and CTpost-PVE.
Data collection and statistical evaluation
Baseline patient characteristics were collected retrospectively by
reviewing patients’ charts. Liver and tumour volumes were cal-
culated from CT transversal plane images.17,18 Analyses were
carried out to compare tumour progress between the right and
the left lobe, thereby comparing tumour progress between the
embolized and non-embolized liver lobe. Data on the right-
sided tumors were compared with data on the left-sided
tumours within the entire population of both patients with
bilobar disease, as well as those with unilobar metastases.
Statistical analysis was performed using SPSS software (IBM
SPSS Statistics for Windows, Version 21.0, IBM Corp.,
Armonk, NY, USA).
Median values (range) describe continuous variables whereas
frequencies were calculated for categorical variables. RECIST
classification was compared between groups and specifically
the percentage of cases that showed progressive disease. Fish-
er’s Exact Test was used to test for statistical significance. The
tumour volume change, as described above, was compared
between groups using the Mann–Whitney U-test. Correlation
between the tumour growth rate and time between the end of
chemotherapy and the time of PVE was calculated using linear
regression analysis and computing a Pearson’s correlation coef-
ficient, r. P-values of <0.05 were considered to represent statis-
tical significance.
The study was approved by the local human ethical committee
at Lund University, Lund and Karolinska University Hospital,
Stockholm.
Results
Patients
A total of 34 CRC patients, subjected to PVE prior to planned
resection of liver metastases, were included for analysis. Patient
characteristics are shown in Table 1.
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A total of 23 patients had bilobar liver metastases, according
to the definition described above.
All patients received chemotherapy prior to PVE. In approxi-
mately two-thirds of the patients, oxaliplatin-based therapy was
applied, whereas most others were treated with irinotecan-based
therapy. The median number of administered cycles was seven
and about half of all patients also received targeted therapy, such
as bevacizumab, cetuximab, panitumumab and erlotinib.
PVE was carried out as described previously17 using the
embolizing agents polyvinyl alcohol particles in 30 patients and
with n-butyl-2-cyanoacrylate in the remaining four cases. All
patients underwent ipsilateral embolization of Couinaud’s
segments 5–8. Segment 4 is not routinely embolized in our
institutions, and no included patient had embolization of seg-
ment 4.
Seventeen patients were eventually operated with an
extended right-sided hemihepatectomy, whereas a right-sided
hemihepatectomy was performed in nine patients. Another
eight patients were not resected owing to extrahepatic tumour
progress (3 patients), insufficient growth of the lateral segment
after PVE (3 patients), strong progress of metastases in both
liver lobes (1 patient) and one new unresectable metastasis
detected peri-operatively in the FLR (1 patient).
Of the total of 26 resections performed, 23 were deemed
radical on microscopic pathological analysis. Figs 1 and 2 show
an example of a patient with multiple tumours in the FLR
treated with chemotherapy and PVE.
Tumour progress
Tumour progress in the right lobe was analysed for all patients
(n = 34) and tumour progress in the left lobe was analysed in
patients with bilobar disease (n = 23). Results on tumour pro-
gress, comparing metastases in the embolized lobe to those in
the non-embolized lobe, are shown in Table 2. There was no
difference in tumour growth between the embolized and non-
embolized liver lobe after embolization (Table 2). There was a
linear correlation between the volumetric tumour growth
and time between the end of chemotherapy and PVE (r = 0.25,
P = 0.0005).
In 9/23 of patients with left lobe disease, tumours disap-
peared on the CT images after PVE. Six of these patients did
show remaining sub-centimeter tumour burden in the left liver
lobe intra-operatively as imaged by contrast-enhanced ultraso-
nography. Of those, five were treated with resection and one
was deemed unresectable because of liver tumour progress.
Two patients showed no evidence of a left-sided tumour intra-
operatively, and thus no resection was performed on the left
lobe. The ninth patient was never operated on owing to extra-
hepatic tumour progress.
Three cases of progressive liver disease were noted after PVE
of tumours in the embolized as well as non-embolized lobe,
representing 3/34 and 3/23 of cases, respectively (P = 0.677).
Discussion
This study shows a lower probability of progressive liver dis-
ease after PVE as compared with previous reports. If there is at
least tumour stabilization on pre-embolization chemotherapy,
progressive liver disease using RECIST criteria was found in
the right liver lobe in 3/34 of patients, and 3/23 of patients
with pre-embolization tumour burden in the left lobe. This
translated into 2/34 patients not resected because of liver
tumour progress. A tumour response after PVE has previously
been investigated to a limited extent, and only one previous
study has evaluated tumour response after PVE according to
Table 1 Patient characteristics
Characteristics (n = 34) Value range or %
Median age (years) 66 49–83
Male gender 21 62%
Median BMI 25 20–36
Synchronous metastases 28 82%
Median number of liver metastases 4 1–17
Median size of largest metastasis (mm) 50 15–192
Chemotherapy before PVE
Oxaliplatin based 23 68%
Irinotecan based 9 27%
Both successively 1 3%
Missing value 1 3%
Median number of
chemotherapy cycles
7 1–27
Targeted therapy 16 47%
Median time between
chemotherapy and PVE (days)
16 2–54
Median time between
CTpre-chemo and CTpre-PVE (days)
142 22–546
Median time between
CTpre-PVE and PVE (days)
34 1–92
Median time between
PVE and CTpost-PVE (days)
29 18–43
Median tFLV (ml) 1544 1130–2524
Median FLR before PVE (ml) 285 133–796
Median FLR% before PVE 19 10–32
Median FLR after PVE (ml) 448 197–1032
Median FLR% after PVE 29 13–52
Liver resection
Right-sided hemih
epatectomy
9 26%
Extended right-sided
hemihepatectomy
17 50%
No resection 8 24%
BMI, body mass index; PVE, portal vein embolisation; CTpre-chemo, CT
before chemotherapy; CTpre-PVE, CT before PVE; CTpost-PVE, CT after
PVE; tFLV, total functional liver volume; FLR, future liver remnant.
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RECIST criteria.13 In the study by Fischer et al.,13 a rate of
tumour progression of 34% after PVE was reported. However,
it is difficult to compare these results as, in the above study,
no details are mentioned about chemotherapy before PVE.
Using the measurement of tumour volume, the results of
the present study differ from previous studies in that we found
a decrease in tumour volume after PVE of 16% in right-sided
tumors and of 11% in left-sided tumors. Simoneau et al.19
reported a large cohort of patients undergoing PVE after
chemotherapy and they found a significant tumour growth
after PVE. There was, however, a difference in the time interval
from the ending of chemotherapy to PVE of 4 weeks in the
above study, as compared with 16 days in the present study.
The study by Pamecha et al.12 also reported an increase in
tumour diameter after PVE. Although all patients were
reported to have received pre-PVE chemotherapy, the details
were not reported including chemotherapy response or time
between the ending of chemotherapy and PVE, making com-
parison with the present study difficult.
Tumour regression after chemotherapy and PVE has, how-
ever, been reported previously. In the study by Pommier
et al.14 tumour shrinkage of 4% in the right lobe and 9% in
the left lobe was observed in patients with a ‘fast response’ to
chemotherapy before PVE. The time interval between chemo-
therapy and PVE was also longer in that study as compared
with the present study, which could, again, explain the differ-
ences between studies. Not very surprisingly, although not
previously analysed, the present study showed that the longer
the time between the end of chemotherapy and PVE, the
greater the tumour growth.
The presented findings could potentially, if corroborated in
larger studies, have important consequences for the operative
strategy of the individual patient. With a low probability for
tumour progression in the FLR after PVE, some patients today
scheduled for a TSH with the intention of clearing the FLR
from the tumour during the first-stage operation, could instead
be managed by percutaneous PVE and a subsequent one-stage
operation. Even patients with multiple tumours in the FLR can
be managed in this way (Fig. 1). A key factor for this, to be
successful, seems to be a short interval between the end of che-
motherapy and PVE. TSH is used in the case of bilobar disease
Figure 2 The patient from Fig. 1 was operated with an extended
right-sided hepatectomy plus five local resections in the lateral
segment 4 weeks after portal vein embolization. Microscopic
examination could reveal in total 10 metastases all with clear
resection margins
A
B
C
Figure 1 (a) Example of a patient with multiple metachronous liver
metastases from rectal cancer involving all liver segments except
the caudate lobe. (b) After nine cycles of oxaliplatin-based
chemotherapy, there was a significant tumour regression. (c) After
portal vein embolization. Embolization material is shown in the
right portal veins
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deemed not resectable through a single operation because of a
too small liver remnant. In TSH, a common strategy is to clear
the future liver remnant from the tumour at the first operation
combined with PVE.20
In TSH, the percentage of patients eventually undergoing
the two planned operations has been evaluated to be 77% in a
recent review.21 After PVE a curative resection rate of 60–82%
has been reported.22 In the present study, the curative resection
rate was 76%. Three out of 34 patients were not resected
because of insufficient hypertrophy of the FLR. Recent data
suggest that by using the ALPPS procedure, this number can
be decreased.23
In a high proportion of patients (41%) with an initial
tumour in the left liver lobe, the tumour disappeared on CT
images after chemotherapy and PVE. However, disappearing
liver metastases on cross-sectional imaging does not mean a
cure in the majority of cases.24 Intra-operative contrast-
enhanced ultrasonography helps to identify many of these
lesions.25 Accordingly, in most patients with disappearing left-
sided lesions on CT imaging, tumours were still identified in
the left lobe intra-operatively by contrast-enhanced ultrasound.
In the two cases without intra-operatively detectable tumours
in the FLR, no resection was undertaken. How to handle the
issue of intra-operatively disappearing liver metastases is some-
what controversial.24 In the study by Arita et al. out of seven
unresected disappearing liver metastases not identifiable by
intra-operative contrast-enhanced ultrasound, three recurred
during follow-up.25
It has been suggested that chemotherapy before PVE will
limit liver regeneration. Prolonged pre-PVE chemotherapy has
been associated with reduced volume gain in the non-embol-
ized lobe,17,26 but other studies have failed to show any influ-
ence of chemotherapy on regeneration.27,28 In the present
study of right-sided PVE, the median FLR increased from 19%
to 29%, which is similar, although somewhat lower, to what
has been reported in previous studies.26,27
There have been few studies on the effect of the type of
embolization material on growth of the future liver remnant. In
the present study polyvinyl alcohol particles were used in most
cases, whilst both a study on pigs29 and later a retrospective
Table 2 Liver tumour growth
Embolized lobe Non-embolized lobe P-value
n = 34 range or % n = 23 range or %
RECIST comparing CTpre-PVE to CTpre-chemo
a
CR 0 0% 3 14%
PR 17 52% 11 50%
SD 16 49% 8 36%
PD 0 0% 0 0%
RECIST comparing CTpost-PVE to CTpre-PVE
CR 1 3% 5 22%
PR 5 15% 1 4%
SD 25 74% 14 61%
PD 3 9% 3 13%
PD after PVE 3 9% 3 13% 0.677
RECIST comparing CTpost-PVE to CTpre-chemo
a
CR 1 3% 9 41%
PR 19 58% 6 27%
SD 10 30% 4 18%
PD 3 9% 3 14%
PD after both chemotherapy and PVEa 3 9% 3 14% 0.674
Median tumour volume CTpre-chemo (ml) 67 3–2185 7 1–125
Median tumour volume CTpre-PVE (ml) 22 1–712 2 0–152
Median tumour volume CTpost-PVE (ml) 17 0–443 1 0–178
Median tumour volume change during chemotherapy (% of previous volume) 40 3–201 26 0–122 0.268
Median tumour volume change after PVE (% of previous volume) 84 0–250 89 0–160 0.368
an = 33 in the embolized lobe and n = 22 in the non-embolized lobe because one patient had no CTpre-chemo as chemotherapy was started right
before PVE.
PVE, portal vein embolization; CTpre-chemo, CT before chemotherapy; CTpre-PVE, CT before PVE; CTpost-PVE, CT after PVE; CR, complete remission;
PR, partial regress; SD, stabile disease; PD, progressive disease.
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analysis of portal vein embolization in humans30 have shown a
superior effect of n-butyl-2-cyanoacrylate as compared to parti-
cles.
The patients in this study all received pre-procedural chemo-
therapy, and since in practice patients who progressed during
chemotherapy often were not offered PVE, these results should
be interpreted with caution and only generalized to patients
responding to chemotherapy. In addition, the number of
included patients was limited, warranting further investigations
to support the presented results.
There have been concerns about the tumour growth-pro-
moting effect of PVE.11 Previous studies have seldom analysed
tumour growth in the non-embolized lobe specifically. As
patients undergoing PVE most often are planned to be oper-
ated with a right-sided or extended right-sided liver resection,
tumour growth in the right lobe would not pose as an
important factor as growth in the left lobe when determining
resectability. After PVE the arterial blood flow to the embolized
lobe increases, described as the hepatic arterial buffer response,31
preserving hepatic viability, whereas the lack of portal venous
flow reduces the total blood flow and causes atrophy in this lobe.
The non-embolized lobe receives an increased portal venous flow
and this together with an increased release of cytokines and
growth factors is believed to induce hypertrophy.32 However, rel-
atively the arterial flow to the non-embolized lobe is decreased.31
Although pronounced changes in intrahepatic blood perfusion
occur after PVE in addition to the fact that liver metastases are
regarded to depend mainly on arterial blood supply,33 this does
not seem to affect the growth of tumours in the left and right
lobe differently. In the present study, the outcomes suggest that
tumour growth in the right and left liver lobe after PVE is com-
parable. This is in accordance with two previous studies investi-
gating the subject.13,14
Conclusion
This study shows that the rate of liver tumour growth after
PVE is lower as compared with previous reports of the
condition of tumour stabilization on pre-embolization chemo-
therapy. It is one of the first studies showing comparable
tumour progression in the non-embolized lobe to that in the
embolized lobe. A short interval between the end of chemo-
therapy and PVE is proposed to be essential for the presented
results.
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